PLA2G7 anticorps (AA 301-441)

N° du produit ABIN686722

Détail du produit anti-PLA2G7 anticorps

Antigène: PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))

Épitope: AA 301-441

Reactivité: Humain, Souris, Rat, Porc, Lapin

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PLA2G7 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Réactivité croisée: Humain, Souris, Porc, Lapin, Rat

Homologie: Dog

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human PAFAH2

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
ELISA 1:500-1000
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Date de péremption: 12 months

Références pour anticorps anti-PLA2G7 (ABIN686722)

Han, Wang, Zhang, Liu, Li, Wang, Song, Pang, Ouyang, Tang: "Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NF?B pathways." dans: Biology open, Vol. 4, Issue 5, pp. 661-5, (2015) (PubMed).

Wang, Ji, Li, Han, Guo, Song, Quan, Wang, Han, Pang, Ouyang, Tang: "Nitro-oleic acid downregulates lipoprotein-associated phospholipase A2 expression via the p42/p44 MAPK and NF?B pathways." dans: Scientific reports, Vol. 4, pp. 4905, (2014) (PubMed).

Rosing, Fobker, Kannenberg, Gunia, DellAquila, Kwiecien, Stypmann, Nofer: "Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients." dans: Atherosclerosis, Vol. 230, Issue 1, pp. 164-70, (2013) (PubMed).

Détails sur PLA2G7

Antigène: PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))

Autre désignation: PAFAH (Lp-PLA2 Produits)

Synonymes: anticorps LDL-PLA2, anticorps LP-PLA2, anticorps PAFAD, anticorps PAFAH, anticorps Lp-PLA2, anticorps PAF-AH, anticorps R75400, anticorps zgc:77563, anticorps phospholipase A2 group VII, anticorps phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma), anticorps PLA2G7, anticorps Pla2g7, anticorps pla2g7

Sujet:

Synonyms: PAFAD, PAFAH, LP-PLA2, LDL-PLA2, Platelet-activating factor acetylhydrolase, PAF acetylhydrolase, 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycerophosphocholine esterase, Group-VIIA phospholipase A2, gVIIA-PLA2, LDL-associated phospholipase A2, LDL-PLA(2), PAF 2-acylhydrolase, PLA2G7

Background: Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids.

ID gène: 7941

UniProt: Q13093

Pathways: Peptide Hormone Metabolism